CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer
Our findings highlight CXCR6 as a critical biomarker for predicting prognosis and immunotherapeutic response in MIBC.
Authors
- Zhaopei Liu (ORCID: https://orcid.org/0000-0002-5288-5037)
- Xiaolin Lü (ORCID: https://orcid.org/0000-0002-0932-8489)
- Yuan Chang (ORCID: https://orcid.org/0000-0003-1125-4041)
- Yu Zhu (ORCID: https://orcid.org/0000-0002-3332-5202)
- Dingwei Ye (ORCID: https://orcid.org/0000-0002-5683-0260)
- Li‐Ping Ge (ORCID: https://orcid.org/0000-0002-3578-0073)
Institutions
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-11
- DOI
- https://doi.org/10.3389/fonc.2024.1498579
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Gilead Sciences
- Beijing Xisike Clinical Oncology Research Foundation
- China Postdoctoral Science Foundation